1. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194:S3–S11.
3. Chesnut CH III. Osteoporosis, an underdiagnosed disease. JAMA 2001;286:2865–2866.
4. Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003;163:2165–2172.
5. Gehlbach SH, Avrunin JS, Puleo E, et al. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 2007;18:805–810.
6. Gallagher TC, Geling O, Comite F. Missed opportunities for prevention of osteoporotic fracture. Arch Intern Med 2002;162:450–456.
7. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–1022.
8. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003–1008.
9. Sokolowski MJ, Jackson AP, Haak MH, et al. Acute outcomes of cervical spine injuries in the elderly: atlantaxial vs subaxial injuries. J Spinal Cord Med 2007;30:238–242.
10. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–475.
11. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001;12:519–528.
12. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522–532.
13. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–1460.
14. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462–466.
15. Fosamax [Package Insert]. Whitehouse Station, NJ, Merck and Company, 2005.
16. Boniva Tablets [Package Insert]. Nutley, NJ, Roche Laboratories, 2006.
17. Actonel [Package Insert]. Cincinnati, Ohio, Proctor and Gamble Pharmaceuticals, 2007.
18. Boniva Injection [Package Insert]. Nutley, NJ, Roche Laboratories, 2007.
19. Reclast [Package Insert]. East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2007.
20. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669–683.
21. Rizzoli R. Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res 2006;443:61–65.
22. Fosamex Plus D [Package Insert]. Whitehouse Station, NJ, Merck and Company, 2007.
23. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118–4124.
24. Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189–1199.
25. Sambrook PN, Rodriguez JP, Wasnich RD, et al. Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 2004;15:483–488.
26. Actonel with Calcium [Package Insert]. Cincinnati, Ohio, Proctor and Gamble Pharmaceuticals, 2006.
27. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trail. Vertebral Efficacy with Risedronate Therapy (VETR) Study Group. JAMA 1999;282:1344–1352.
28. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–340.
29. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631–2637.
30. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25–34.
31. Reginster JY. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des 2005;11:3711–3728.
32. Chesnut CH III, Skag A, Christiansen C, et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–1249.
33. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654–661.
34. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005;27:361–376.
35. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.
36. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–861.
37. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.
38. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414–2419.
39. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–1903.
40. Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 2006;4:21–27.
41. Reginster JY, Felsenberg D, Cooper C, et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 2006;17:159–166.
42. Squier RW. A model of empathic understanding and adherence to treatment regimens in practitioner-patient relationships. Soc Sci Med 1990;30:325–339.
43. Neuwirth ZE. An essential understanding of physician-patient communication. Part II. J Med Pract Manage 1999;15:68–72.
44. Kerse N, Buetow S, Mainous AG III, et al. Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med 2004;2:455–461.
45. Maly RC Leake B, Frank JC, et al. Implementation of consultative geriatric recommendations: the role of patient-primary care physician concordance. J Am Geriatr Soc 2002;50:1372–1380.
46. Williams N, Ogden J. The impact of matching the patient’s vocabulary: a randomized control trial. Fam Pract 2004;21:630–635.
47. Smith VA, DeVellis BM, Kalet A, et al. Encouraging patient adherence: primary care physicians’ use of verbal compliance-gaining strategies in medical interviews. Patient Educ Couns 2005;57:62–76.